Avenue Therapeutics Inc (ATXI) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
Avenue Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period
Return on Assets, Quarterly Results, Trends, Rankings, Statistics
What is Avenue Therapeutics Inc 's ROA in the second quarter of 2026?
Avenue Therapeutics Inc recorded a cumulative net loss of $-3 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -101.01%.
However, within the Healthcare sector 739 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3965, from total ROA ranking in the first quarter of 2026 at 4887.
In the world of biotech investments, dynamic share performance can often reflect not just the inherent qualities of the companies involved but also the broader market sentiments and strategic decisions that shape investor confidence. Recent news surrounding Avenue Therapeutics Inc. (ATXI) and Protagenic Therapeutics (PTIX) has highlighted fluctuating market conditions and the financial viability of smaller biotech firms, raising pivotal questions for investors evaluating potential risks and rewards.Avenue Therapeutics has recently captured attention due to its striking decline in share value, trading at a startling -96.70% below its 52-week high and just slightly above its 52-week low. On July 24, 2024, the stock was reported to have hit a new low of $3.18, prompting concerns about the firm s ongoing viability. Notably, Avenue recorded a cumulative net loss of $7 million in the 12 months ending in the first quarter of 2024, resulting in an alarming return on assets (ROA) of -412.37%. Comparatively, out of 657 companies within the Healthcare sector, Avenue ranks lower in terms of asset efficiency, confirming difficult operational challenges that may hamper its long-term prospects.
In an exciting development for the healthcare industry, Avenue Therapeutics has recently published a groundbreaking study showcasing the preclinical data of their first-in-class drug, BAER-101, in the treatment of absence epilepsy. The drug has demonstrated a unique ability to significantly suppress seizures in a translational model of absence epilepsy, utilizing the Genetic Absence Epilepsy Rat from Strasbourg (GAERS) model. While this achievement is remarkable, it comes at a time when the company has faced financial challenges, recording a substantial net loss of $11 million and experiencing a negative return on assets (ROA) of -246.79% during the past 12 months. Facts: 1. Avenue Therapeutics has published an article highlighting the preclinical data of BAER-101, a potential breakthrough treatment for absence epilepsy, in Drug Development Research. 2. BAER-101 demonstrated significant seizure suppression capabilities in a translational model of absence epilepsy, using the SynapCell s GAERS model. 3. Avenue Therapeutics has recorded a cumulative net loss of $-11 million during the twelve months ending in the third quarter of 2023. 4. The negative ROA of -246.79% indicates that the company s assets did not generate sufficient profits during this period. 5. Within the healthcare sector, Avenue Therapeutics lags behind 969 other companies with higher ROAs. 6. The overall ranking for Avenue Therapeutics ROA has improved from 4969 in the second quarter of 2023 to 4673 in the third quarter of 2023.
Avenue Therapeutics Raises $5 Million in Proceeds through Warrant Exercise Transactions Miami, January 5, 2024 - Avenue Therapeutics, a specialty pharmaceutical company specializing in the development and commercialization of therapies for neurologic diseases, has announced its entry into warrant exercise agreements with existing accredited investors. Under these agreements, certain outstanding warrants to purchase a total of 16.5 million shares of the company s common stock will be immediately exercised. The warrants for immediate exercise include the November 2023 Series B warrants, allowing the purchase of 14.6 million shares of common stock at an exercise price of $0.3006 per share, and the January 2023 warrants, allowing the purchase of 1.9 million shares of common stock at an exercise price of $1.55 per share. However, the exercise price for the January 2023 warrants has been reduced to $0.3006 per share as agreed upon by the company. Avenue Therapeutics expects the gross proceeds from the warrant exercise transactions to be approximately $5.0 million, before deducting the placement agent fees and estimated offering expenses. The closing of the transactions is anticipated to take place around January 9, 2024, subject to the fulfillment of customary closing conditions.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
